An independent reading desk for the GHK-Cu literature

What this project is

GHK-Cu Rx is an independent editorial project that publishes summaries of the peer-reviewed research literature on GHK-Cu, the copper tripeptide. We are not a clinic. We do not employ clinicians and we do not provide medical advice. We do not manufacture, sell, or distribute any product. Our work is editorial commentary on publicly available science.

The "Rx" in the name is a register, not a service. It signals a careful, plain-spoken, dispensary-of-the-literature posture — dispensing the published record exactly as it reads, with the strong preclinical findings and the thin human evidence weighed in the same frame. It is not a claim that this site prescribes, consults, or treats. No prescription is written here and none can be.

What a copper peptide is

Because the term recurs across every page, it is worth defining plainly here too: a copper peptide is a short peptide that chelates a copper ion, stabilizing the metal and tuning its reactivity. GHK-Cu — glycyl-L-histidyl-L-lysine bound 1:1 to copper(II), molecular weight 402.92 Da — is the archetype, and its very high copper stability constant (log K around 16.4) is what keeps free-copper release low ^[3]. On a cosmetic label the same molecule is named Copper Tripeptide-1. The research we summarize is overwhelmingly about this one compound, read precisely, with GHK (the copper-free peptide) kept distinct because copper coordination is required for most documented activity ^[7].

Copper peptide side effects reported in the record

On copper peptide side effects, the editorial duty is to report what the record contains rather than to reassure. The most commonly reported topical issue is localized hyperpigmentation with some copper-peptide applications, and a 13-patient post-CO2-laser study found no objective benefit despite higher patient satisfaction ^[5]. Free copper is theoretically pro-oxidant, but the GHK-Cu chelate's high stability constant limits its release, and no human copper-toxicity cases attributed to GHK-Cu appear in the peer-reviewed record ^[3]. A formulation hazard is well-documented: vitamin C and low-pH acids can reduce the copper and destroy both actives ^[8]. No long-term human safety data exist for systemic use, which is research-only. We state these as findings and gaps, not as clearance.

How we read the record

Every quantitative claim on this site is tied to a study in the GHK-Cu references and citations. When the literature is strong — the picomolar collagen dose-response ^[1], the genome-wide expression signature ^[2] — we say so. When it is thin — no validated human pharmacokinetics, a single combination-formula hair trial ^[4] — we say that too, and we flag where a cited study used an analog or a combination rather than pure GHK-Cu. Much of the foundational work originates from one investigator and colleagues, so independent replication of the broader claims is still limited. We keep the strong record and the gaps visible in the same view.